Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00111670 · ClinicalTrials.gov registry record · Phase 2

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 2
Development phase
291
Enrollment target
20
Study locations

NCT00111670: Completed Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Hoffmann-La Roche.

NCT00111670 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by Hoffmann-La Roche. The registered enrollment target is 291 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00111670, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 2
Development phase
291 participants
Enrollment target
20
Study locations

Study Summary

This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor compared to placebo in patients with type 2 diabetes. The anticipated time on study treatment is \< 3 months and the target sample size is 100-500 individuals.

Conditions Studied

Diabetes Mellitus, Type 2

Interventions

  • DRUG Placebo
  • DRUG DPP-IV Inhibitor

Study Locations (20)

Florida

  • - Clearwater
  • - Hialeah
  • - Pembroke Pines

Texas

  • - Dallas
  • - Midland
  • - San Antonio

Maryland

  • - Elkton
  • - Oxon Hill

Virginia

  • - Richmond
  • - Virginia Beach

Other

  • - Rousse
  • - Sofia

California

  • - Salinas

Georgia

  • - Blue Ridge

Illinois

  • - Aurora

Trial Details

FieldValue
Enrollment Target 291 participants
Start Date 2005-06
Est. Completion 2006-07
Phase Phase 2
Hoffmann-La Roche

909 total trials

What the finished NCT00111670 record still lists

NCT00111670 is an interventional study that assigns participants to a tested intervention. The registered 291 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00111670 names 20 study sites across 13 states, led by Florida, Texas, Maryland.

Frequently Asked Questions

What is clinical trial NCT00111670 about?

NCT00111670 is a clinical study titled "A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes". This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor compared to placebo in patients with type 2 diabetes. The anticipated time on study treatment is \< 3 months and the target sample size is 100-500 individuals.

What is the current status of trial NCT00111670?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 291 participants. The study started on 2005-06. Estimated completion is 2006-07.

What conditions does trial NCT00111670 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT00111670?

The interventions under investigation include: Placebo (DRUG), DPP-IV Inhibitor (DRUG).

Who is sponsoring clinical trial NCT00111670?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00111670 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00111670's enrollment target sits among peer trials

291 128th of 348 higher than 221 of 348 other Diabetes Mellitus, Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02074839 · 291 participants · Phase 1

    Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

  • NCT03769766 · 291 participants · Phase 3

    Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance

  • NCT06563479 · 291 participants · Phase 3

    A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer

  • NCT04429542 · 292 participants · Phase 1

    Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00111670, the US trial registry maintained by the National Library of Medicine. NCT00111670 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.